On the chart you can see the default numbers in dynamics for Edwards Lifesciences Corporation (EW). Companys revenue shows the average of 2317.808 M which is 0.086 % gowth. The average gross profit for the whole period is 1683.372 M which is 0.103 %. The average gross profit ratio is 0.679 %. The net income growth for the company last year performance is -0.079 % which equals 1.845 % % on average for the whole company history.,
Diving into the fiscal trajectory of Edwards Lifesciences Corporation, we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 0.000. In the realm of current assets, EW clocks in at 4035.7 in the reporting currency. A significant portion of these assets, precisely 1644.5, is held in cash and short-term investments. This segment shows a change of 0.353% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 583.9, if any, in the reporting currency. This indicates a difference of -52.873% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 670 in the reporting currency. This figure signifies a year_over_year change of 0.000%. Shareholder value, as depicted by the total shareholder equity, is valued at 6650 in the reporting currency. The year over year change in this aspect is 0.145%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 836.9, with an inventory valuation of 1168.2, and goodwill valued at 1253.5, if any. The total intangible assets, if present, are valued at 428.4.
The financial landscape of Edwards Lifesciences Corporation has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of -0.995. The company recently extended its share capital by issuing 169.9, marking a difference of 0.650 compared to the previous year. The company's investing activities resulted in net cash usage, amounting to 173800000.000 in the reporting currency. This is a shift of -0.311 from the previous year. In the same period, the company recorded 144.9, -75, and -0.3, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -169.9 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 168.9, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.
Edwards Lifesciences Corporation's revenue saw a change of 0.116% compared with the previous period. The gross profit of EW is reported to be 4625. The company's operating expenses are 2895.2, showing a change of 15.218% from the last year. The expenses for depreciation and amortization are 144.9, which is a 0.780% change from the last accounting period. Operating expenses are reported to be 2895.2, which shows a 15.218% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -0.123% year-over-year growth. The operating income is 1534.1, which shows a -0.123% change when compared to the previous year. The change in the net income is -0.079%. The net income for the last year was 1402.4.
